MULTICENTER, OPEN-LABEL EXPANDED ACCESS PROGRAM OF TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH HER2 MUTATED METASTATIC/LOCALLY-ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

eno Shizuko0 个研究点目标入组 30 人开始时间: 2023年1月30日最近更新: 2024年5月27日

试验速览

阶段: Unknown
状态: 已完成
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•1) Must have provided informed consent for study participation before performance of any study-specific procedure or test.
•2) Men or women >= 18 years old.
•3) Pathologically documented metastatic/locally advanced NSCLC with a known activating HER2 mutation. The HER2 mutation must be documented from an archival or fresh tumor tissue sample analyzed by laboratory performing testing to Good Laboratory Practice (GLP) standard.
•Note: HER2 mutation documented only from a liquid biopsy sample cannot be used for enrollment.
•4) Subjects who had previous treatment including platinum therapy in the metastatic/locally advanced setting and not amenable to curative surgery or radiation. The subject must have progressed during or after the last treatment regimen or discontinued because of unacceptable toxicity.
•5) Has ECOG PS of 0 to 1.
•6) Has left ventricular ejection fraction (LVEF) >= 50% within 28 days before enrollment.
•7) Has adequate organ and bone marrow function within 28days before randomization/enrollment. Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 2 weeks prior to randomization. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days of randomization/enrollment as appropriate. Adequate organ/bone marrow function
•8) Has adequate treatment washout period before enrollment
•9) Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males, after the last dose of study drug.
•10) Male subjects must not freeze or donate sperm starting at enrollment and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study.
•11) Female subjects must not donate, or retrieve for their own use, ova from the time of enrollment and throughout the study treatment period, and for at least 7 months after the final study drug administration. Female subjects must refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrollment in this study.

排除标准

•1) Medical history of myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV. Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation before enrollment to rule out MI.
•2) Has a corrected QT interval (QTcF) prolongation > 470 msec (females) or >450 msec (males) based on average of triplicate12-lead ECG at screening.
•3) Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
•4) Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and study enrollment.
•5) Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated.
•6) Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
•7) Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
•8) Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
•9) Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
•10) Active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Subjects should be tested for HIV prior to randomization/enrollment if required by local regulations or institutional review board (IRB)/ethics committee (EC).
•Subjects with past or resolved hepatitis B virus (HBV) infection are eligible only if they meet all of the following criteria*:
•- HBsAg(-) (for > 6 months off anti-viral treatment)
•- Anti-HBc(+) (IgG or total Ig)
•- HBV DNA undetectable
•- Absence of cirrhosis or fibrosis on prior imaging or biopsy
•- Absence of HCV co-infection or history of HCV co-infection
•- Access to a local Hepatitis B expert during and after the study
•Such participants should be closely monitored for HBV reactivation.
•*Note to author: Consideration should be given to exclusion of all participants with HBV infection if comparator or combination study treatments are associated with a high risk of HBV infection reactivation and are incompatible with anti-viral medications.
•11) Has history of receiving live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.
•12) Unresolved

研究者

发起方

eno Shizuko

相似试验

进行中（未招募）

1 期

Access Program for Asfotase AlfaHypophosphatasia

EUCTR2015-000809-39-FRAlexion Pharma International Sàrl100

进行中（未招募）

不适用

An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.

EUCTR2011-002731-26-ITOVARTIS FARMA700

进行中（未招募）

不适用

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies

EUCTR2009-017671-22-BEEisai Limited500

进行中（未招募）

1 期

EUCTR2014-001700-21-DEAmgen Inc.100

进行中（未招募）

1 期

Clinical Study with the bispecific antibody Blinatumomab in pediatric and adolescent subjects with B-precursor Acute Lymphoblastic Leukemia (ALL) who did not respond to previous therapy or who relapsed after initial successful previous therapyPediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)MedDRA version: 17.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10066109Term: Precursor B-lymphoblastic leukemia acuteSystem Organ Class: 100000004864

EUCTR2014-001700-21-ITAmgen Inc.110